Ars Pharmaceuticals Inc (SPRY) Stock Price, Quote & News

Company Profile

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 858 771 9307

Website: ars-pharma.com

Address:

11682 El Camino Real, Suite 120, San Diego, United States

jmciv Mar. 17 at 8:21 PM

$MIST At most an $8 stock. $SPRY is a one trick pony as well. A merger would be ideal. Have been holding a year now. I expect ER will provide a much needed boost.

4 · Reply

FortheLoveofStockz Mar. 17 at 8:13 PM

$SPRY I just got in, saw the ad, know numerous people that deal with this. let's take a ride and see where it goes.

1 · Reply

ThinkVision Mar. 17 at 5:38 PM

$SPRY

0 · Reply

ThinkVision Mar. 17 at 4:01 PM

$CADL $SPRY bull case: Needle-free neffy hammer 2025 w/ $72M US rev, $245M cash to breakeven. Catalysts: Japan launch Q1’26 (Alfresa), Canada approval/launch Q2’26 (ALK), urticaria Ph2b data mid’26 (TAM doubler to $2B+ US). 98% global moat—approvals: US (FDA 2mg/1mg), EU (EURneffy 2mg/1mg w/ CHMP Jan’26), China (NMPA Dec’25 via Pediatrix), Australia (TGA Dec’25 2mg/1mg via CSL Seqirus), New Zealand (via CSL Seqirus partnership). Wartime/econ resilient: Essential med demand surges in conflicts/downturns like #IranWar tensions or #WarEconomy slumps. Comps re-rate 300%+; 48% short float = squeeze potential. DCF $16-25+! 🚀 #Biotech #SPRY #Investing #EconomicDownturn #GeopoliticalRisk #iran #war #worldwar #navy #army #marines

1 · Reply

ThinkVision Mar. 17 at 2:58 PM

$RDDT $SPRY bull case: Needle-free neffy pounds 2025 w/ $72M US rev, $245M cash to breakeven. Catalysts: Japan launch Q1’26 (Alfresa), Canada approval/launch Q2’26 (ALK), urticaria Ph2b data mid’26 (TAM doubler to $2B+ US). 98% global moat—approvals: US (FDA 2mg/1mg), EU (EURneffy 2mg/1mg w/ CHMP Jan’26), China (NMPA Dec’25 via Pediatrix), Australia (TGA Dec’25 2mg/1mg via CSL Seqirus), New Zealand (via CSL Seqirus partnership). Wartime/econ resilient: Essential med demand surges in conflicts/downturns like #IranWar tensions or #WarEconomy slumps. Comps re-rate 300%+; 48% short float = squeeze potential. DCF $16-25+! 🚀 #Biotech #SPRY #Investing #EconomicDownturn #GeopoliticalRisk #iran #war #worldwar #navy #army #marines

0 · Reply

ThinkVision Mar. 17 at 2:58 PM

$RKLB $SPRY bull case: Needle-free neffy (only new epi pen alternative) smashes 2025 w/ $72M US rev, $245M cash to breakeven. Catalysts: Japan launch Q1’26 (Alfresa), Canada approval/launch Q2’26 (ALK), urticaria Ph2b data mid’26 (TAM doubler to $2B+ US). 98% global moat—approvals: US (FDA 2mg/1mg), EU (EURneffy 2mg/1mg w/ CHMP Jan’26), China (NMPA Dec’25 via Pediatrix), Australia (TGA Dec’25 2mg/1mg via CSL Seqirus), New Zealand (via CSL Seqirus partnership). Wartime/econ resilient: Essential med demand surges in conflicts/downturns like #IranWar tensions or #WarEconomy slumps. Comps re-rate 300%+; 48% short float = squeeze potential. DCF $16-25+! 🚀 #Biotech #SPRY #Investing #EconomicDownturn #GeopoliticalRisk #iran #war #worldwar #navy #army #marines

0 · Reply

ThinkVision Mar. 17 at 2:57 PM

$NVDA $SPRY bull case: Needle-free neffy makes hay 2025 w/ $72M US rev, $245M cash to breakeven. Catalysts: Japan launch Q1’26 (Alfresa), Canada approval/launch Q2’26 (ALK), urticaria Ph2b data mid’26 (TAM doubler to $2B+ US). 98% global moat—approvals: US (FDA 2mg/1mg), EU (EURneffy 2mg/1mg w/ CHMP Jan’26), China (NMPA Dec’25 via Pediatrix), Australia (TGA Dec’25 2mg/1mg via CSL Seqirus), New Zealand (via CSL Seqirus partnership). Wartime/econ resilient: Essential med demand surges in conflicts/downturns like #IranWar tensions or #WarEconomy slumps. Comps re-rate 300%+; 48% short float = squeeze potential. DCF $16-25+! 🚀 #Biotech #SPRY #Investing #EconomicDownturn #GeopoliticalRisk #iran #war #worldwar #navy #army #marines

0 · Reply

ThinkVision Mar. 17 at 2:56 PM

$UBER $SPRY bull case: Needle-free neffy hammers 2025 w/ $72M US rev, $245M cash to breakeven. Catalysts: Japan launch Q1’26 (Alfresa), Canada approval/launch Q2’26 (ALK), urticaria Ph2b data mid’26 (TAM doubler to $2B+ US). 98% global moat—approvals: US (FDA 2mg/1mg), EU (EURneffy 2mg/1mg w/ CHMP Jan’26), China (NMPA Dec’25 via Pediatrix), Australia (TGA Dec’25 2mg/1mg via CSL Seqirus), New Zealand (via CSL Seqirus partnership). Wartime/econ resilient: Essential med demand surges in conflicts/downturns like #IranWar tensions or #WarEconomy slumps. Comps re-rate 300%+; 48% short float = squeeze potential. DCF $16-25+! 🚀 #Biotech #SPRY #Investing #EconomicDownturn #GeopoliticalRisk #iran #war #worldwar #navy #army #marines

0 · Reply

ThinkVision Mar. 17 at 2:56 PM

$OKLO $SPRY bull case: Needle-free neffy kills 2025 w/ $72M US rev, $245M cash to breakeven. Catalysts: Japan launch Q1’26 (Alfresa), Canada approval/launch Q2’26 (ALK), urticaria Ph2b data mid’26 (TAM doubler to $2B+ US). 98% global moat—approvals: US (FDA 2mg/1mg), EU (EURneffy 2mg/1mg w/ CHMP Jan’26), China (NMPA Dec’25 via Pediatrix), Australia (TGA Dec’25 2mg/1mg via CSL Seqirus), New Zealand (via CSL Seqirus partnership). Wartime/econ resilient: Essential med demand surges in conflicts/downturns like #IranWar tensions or #WarEconomy slumps. Comps re-rate 300%+; 48% short float = squeeze potential. DCF $16-25+! 🚀 #Biotech #SPRY #Investing #EconomicDownturn #GeopoliticalRisk #iran #war #worldwar #navy #army #marines

0 · Reply

ThinkVision Mar. 17 at 2:55 PM

$OPEN $SPRY bull case: Needle-free neffy smashes 2025 w/ $72M US rev, $245M cash to breakeven. Catalysts: Japan launch Q1’26 (Alfresa), Canada approval/launch Q2’26 (ALK), urticaria Ph2b data mid’26 (TAM doubler to $2B+ US). 98% global moat—approvals: US (FDA 2mg/1mg), EU (EURneffy 2mg/1mg w/ CHMP Jan’26), China (NMPA Dec’25 via Pediatrix), Australia (TGA Dec’25 2mg/1mg via CSL Seqirus), New Zealand (via CSL Seqirus partnership). Wartime/econ resilient: Essential med demand surges in conflicts/downturns like #IranWar tensions or #WarEconomy slumps. Comps re-rate 300%+; 48% short float = squeeze potential. DCF $16-25+! 🚀 #Biotech #SPRY #Investing #EconomicDownturn #GeopoliticalRisk #iran #war #worldwar #navy #army #marines

0 · Reply

ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines

Mar 9, 2026, 10:58 AM EDT - 9 days ago

ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript

Mar 9, 2026, 6:00 AM EDT - 9 days ago

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization

Feb 23, 2026, 8:00 AM EST - 23 days ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences

Feb 13, 2026, 11:24 PM EST - 4 weeks ago

ARS Pharmaceuticals: Climbing Neffy Sales And Global Expansion Could Re-Rate The Stock

Feb 10, 2026, 8:00 AM EST - 5 weeks ago

ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

Feb 2, 2026, 8:00 AM EST - 6 weeks ago

EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to

Jan 21, 2026, 8:00 AM EST - 2 months ago

California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use

Jan 9, 2026, 12:32 PM EST - 2 months ago

Bad News For Competitor Turns Into Big Win For ARS Pharma Stock

Dec 29, 2025, 8:00 AM EST - 2 months ago

neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)

Nov 26, 2025, 8:00 AM EST - 4 months ago

ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

Nov 10, 2025, 2:01 PM EST - 4 months ago

ARS Pharmaceuticals, Inc. (SPRY) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 1:59 PM EST - 4 months ago

ARS Pharmaceuticals: What We Learned From Q3 Earnings - Why I Maintain Hold Rating

Nov 10, 2025, 6:00 AM EST - 4 months ago

ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

Nov 4, 2025, 8:00 AM EST - 4 months ago

ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)

Nov 3, 2025, 2:23 PM EST - 4 months ago

UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Nov 3, 2025, 8:00 AM EST - 4 months ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results

Nov 3, 2025, 7:45 AM EST - 4 months ago

ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 8, 2025, 8:00 AM EDT - 5 months ago

ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)

Sep 29, 2025, 4:05 PM EDT - 6 months ago

ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®

Sep 23, 2025, 2:08 AM EDT - 6 months ago

ARS Pharmaceuticals: A Significant Upside Is Expected From neffy

Sep 17, 2025, 9:00 AM EDT - 6 months ago

ADARx Pharmaceuticals Appoints Industry Veteran, Laura Shawver, Ph.D., as Board Chair

Sep 8, 2025, 8:00 AM EDT - 6 months ago

Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis

Aug 28, 2025, 8:00 AM EDT - 7 months ago

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 13, 2025, 11:53 AM EDT - 7 months ago

ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 7:00 AM EDT - 7 months ago

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)

Aug 4, 2025, 8:00 AM EDT - 8 months ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results

Jul 18, 2025, 9:25 AM EDT - 8 months ago

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

May 14, 2025, 1:32 PM EDT - 11 months ago

ARS Pharmaceuticals, Inc. (SPRY) Q1 2025 Earnings Call Transcript

May 14, 2025, 7:00 AM EDT - 11 months ago

ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

May 7, 2025, 8:00 AM EDT - 11 months ago

ARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

May 5, 2025, 8:00 AM EDT - 11 months ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 11 months ago

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

Apr 30, 2025, 6:51 AM EDT - 11 months ago

ARS Pharmaceuticals Has A Blockbuster Candidate

Mar 20, 2025, 3:31 PM EDT - 1 year ago

ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await

Mar 20, 2025, 1:28 PM EDT - 1 year ago

ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call Transcript

Mar 20, 2025, 7:00 AM EDT - 1 year ago

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 5, 2025, 4:10 PM EST - 1 year ago

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

Mar 3, 2025, 4:35 PM EST - 1 year ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

Feb 20, 2025, 7:02 PM EST - 1 year ago

ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

Feb 18, 2025, 8:00 AM EST - 1 year ago

ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

Feb 6, 2025, 1:04 AM EST - 1 year ago

ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions

Jan 6, 2025, 8:00 AM EST - 1 year ago

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

Dec 19, 2024, 5:25 PM EST - 1 year ago

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

Dec 12, 2024, 2:32 PM EST - 1 year ago

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

Dec 4, 2024, 8:00 AM EST - 1 year ago

ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost

Nov 13, 2024, 12:40 PM EST - 1 year ago

ARS Pharmaceuticals, Inc. (SPRY) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 6:30 AM EST - 1 year ago

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 11, 2024, 7:41 AM EST - 1 year ago

ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024

Nov 11, 2024, 7:00 AM EST - 1 year ago

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

jmciv Mar. 17 at 8:21 PM

$MIST At most an $8 stock. $SPRY is a one trick pony as well. A merger would be ideal. Have been holding a year now. I expect ER will provide a much needed boost.

4 · Reply

FortheLoveofStockz Mar. 17 at 8:13 PM

$SPRY I just got in, saw the ad, know numerous people that deal with this. let's take a ride and see where it goes.

1 · Reply

ThinkVision Mar. 17 at 5:38 PM

$SPRY

0 · Reply

ThinkVision Mar. 17 at 4:01 PM

1 · Reply

ThinkVision Mar. 17 at 2:58 PM

0 · Reply

ThinkVision Mar. 17 at 2:58 PM

0 · Reply

ThinkVision Mar. 17 at 2:57 PM

0 · Reply

ThinkVision Mar. 17 at 2:56 PM

0 · Reply

ThinkVision Mar. 17 at 2:56 PM

0 · Reply

ThinkVision Mar. 17 at 2:55 PM

0 · Reply

Pey_Nova Mar. 16 at 7:58 PM

$SPRY small cap biotech and the setup only gets interesting once volume confirms through the coil

0 · Reply

Stone52 Mar. 16 at 2:07 PM

$SPRY China sales launching. There is no other product for anaphylaxis in China. No needle or needle-free option. Also, Canada approval within 30 days

1 · Reply

Ravery Mar. 13 at 6:09 PM

$AQST $SPRY Aquestive's short interest relatively flat while SI in spry continues to climb to a new 52 week high. Draw your own concusions.

1 · Reply

ThinkVision Mar. 13 at 12:25 PM

$KLAR …. $SPRY $NDAQ ALK expects 425mm USD peak revenue from Neffy not including urticaria. Just launched last year…let’s gooo

0 · Reply

ThinkVision Mar. 13 at 12:24 PM

$IBRX $SPRY $NDAQ ALK expects 425mm USD peak revenue from Neffy not including urticaria. Just launched last year…let’s gooo

0 · Reply

WallStreetBuyDip Mar. 13 at 7:06 AM

$SPRY Trading at $8.24, volume was around 2.1M in the last few sessions, quite in line with its average volume of 1.86M.

0 · Reply

MikeBob15 Mar. 13 at 2:46 AM

$SPRY For some odd reason Anaphalayxs/ allergic reactions rates in the United States are quantifiably higher like 1 in 50 vs 50 per 100,000 for the greater World. NP... hmm🤔

0 · Reply

Lovelylatta Mar. 13 at 1:54 AM

$SPRY are we squeezing or what?

0 · Reply

mikesterz7 Mar. 13 at 1:52 AM

$SPRY ARS Pharmaceuticals, Inc. maintains a Hold rating as neffy’s commercial uptake remains slow despite FDA approval and a robust marketing push.

0 · Reply

ThinkVision Mar. 13 at 1:47 AM

$CF $SPRY $NDAQ ALK expects 425mm USD peak revenue from Neffy not including urticaria. Just launched last year…let’s gooo

2 · Reply

ThinkVision Mar. 13 at 1:47 AM

$LWLG $SPRY $NDAQ ALK expects 425mm USD peak revenue from Neffy not including urticaria. Just launched last year…wow

2 · Reply

ThinkVision Mar. 13 at 1:46 AM

$HIMX $SPRY $NDAQ ALK expects 425mm USD peak revenue from Neffy not including urticaria. Just launched last year…

2 · Reply

Market Cap	833.10M
Revenue (ttm)	89.15M
Net Income (ttm)	8.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-203.25%
Debt to Equity Ratio	1.47

Volume	1,467,700
Avg Vol	1,407,226
Day's Range	N/A - N/A
Shares Out	99.30M
Stochastic %K	49%
Beta	0.78
Analysts	Strong Sell
Price Target	$25.60